Prognostic impact of a 3‐MicroRNA signature in cytological samples of small cell lung cancer
Open Access
- 6 May 2016
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 124 (9) , 621-629
Abstract
BACKGROUND Small cell lung cancer (SCLC) is a highly aggressive neoplasm that accounts for approximately 10% to 15% of lung cancers. In most cases, the diagnosis relies on cytology and needs to be confirmed by immunohistochemistry. Although several genetic and molecular abnormalities have been recorded, molecular markers able to predict the prognosis are still lacking. MicroRNA (miRNA) signatures have been recently proposed as useful biomarkers in lung cancer because of their high stability during standard sample processing. METHODS Cytological samples for 50 patients with SCLC were collected from primary tumors (n = 25) and metastases (n = 25) by means of fine-needle aspiration (FNA) or bronchial washing (BW); they were fixed in ethanol (FNA) or Duboscq-Brazil fluid (BW). The 3-miRNA panel expression (miR-192, miR-200c, and miR-205) was quantified with a TaqMan polymerase chain reaction miRNA assay and was compared with overall survival (OS) and clinicopathological data. RESULTS All samples had sufficient RNA for the miRNA expression analysis to be performed, regardless of the sample source or the fixative medium. Patients with a low expression level of the 3-miRNA panel were associated with better OS in univariate (P = .032) and multivariate analyses (P = .022). Moreover, in the group of patients older than the mean age of our cohort (65.8 years), a significant OS advantage (P = .013) was seen for patients with a low expression level of the 3-miRNA panel. CONCLUSIONS A specific 3-miRNA signature is potentially useful for predicting survival for patients with SCLC, and it may be feasible with cytological samples taken during standard diagnostic procedures. Cancer Cytopathol 2016;124:621–9. © 2016 American Cancer Society.Keywords
Funding Information
- Italian League Against Cancer (Novara, Italy)
This publication has 47 references indexed in Scilit:
- The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung CancerMolecular Therapy, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21WAF1/CIP1British Journal of Cancer, 2014
- Small-Cell Lung Cancer in England: Trends in Survival and Chemotherapy Using the National Lung Cancer AuditPLOS ONE, 2014
- The microcosmos of cancerNature, 2012
- Small-cell lung cancerThe Lancet, 2011
- Causes and consequences of microRNA dysregulation in cancerNature Reviews Genetics, 2009
- MicroRNA Signature Predicts Survival and Relapse in Lung CancerCancer Cell, 2008
- A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenesOncogene, 2006
- MicroRNAs: small RNAs with a big role in gene regulationNature Reviews Genetics, 2004